- Trial Phase
- Filed/PDUFA for Gaucher type 3 (NDA under FDA priority review); Phase 3 ongoing in Fabry disease; Phase 3 GM2 (Tay-Sachs
- Time to Market
- US approval decision for Gaucher type 3 on November 25, 2026 (PDUFA); commercial launch could follow in late 2026/early 2027 if approved. The Fabry Phase 3 is still running (full completion estimated Dec 2027), so a Fabry filing is likely 2028 or later.
- Why 5/10
- The single next hard, dated catalyst is the FDA PDUFA decision on the Gaucher type 3 NDA, target action date November 25, 2026 (priority review) — a real binary within ~4 months, but venglustat is a niche ultrarare-disease asset inside a ~$110B mega-cap, so it is not a major value driver of Sanofi and an approval/rejection will move the ADR only modestly; that caps the score at 5 per the concentration rule.
Watch the November 25, 2026 PDUFA decision for Gaucher disease type 3 — a positive outcome (priority review plus a pivotal study that met both primary endpoints) would be a modest positive for SNY but not a needle-mover given Sanofi's size. More interesting for dedicated investors: whether topline data from the Phase 3 Fabry trial (NCT05280548, primary completion passed May 15, 2026) emerges before year-end, since Fabry is a larger market; the local data shows no results posted yet.
Price Chart
Executive Summary
Venglustat (GZ402671) is Sanofi's oral glucosylceramide-synthase inhibitor in development for rare sphingolipid storage diseases. The headline catalyst is an NDA under FDA priority review for Gaucher disease type 3 — the Phase 3 LEAP2MONO study met both primary endpoints and three of four key secondary endpoints, and approval would make it the first US treatment addressing the neurological manifestations of GD3, with a target action date of November 25, 2026 (per Sanofi's June 8, 2026 6-K). The program has had setbacks — the Phase 3 GM2 (Tay-Sachs/Sandhoff) trial was terminated — and a Phase 3 Fabry trial (n=104) passed its estimated primary completion in May 2026 with no results posted in local data. Because venglustat targets tiny patient populations inside a ~$110B mega-cap, the PDUFA is a genuine dated binary but a small share-price driver for SNY.
How It Works
Venglustat is a daily oral pill that blocks an enzyme (glucosylceramide synthase) that cells use to build a fat-like substance called glucosylceramide. In diseases like Gaucher, Fabry and GM2, this substance builds up to toxic levels. By reducing its production — a strategy called substrate reduction therapy — the drug lowers the toxic buildup. Unlike enzyme-replacement infusions, it is a pill and can cross into the brain, which is why it is being tested for the neurological form of Gaucher (type 3).
Trial Status
Gaucher type 3: Phase 3 LEAP2MONO met both primary endpoints and three of four key secondary endpoints; NDA granted FDA priority review with target action date Nov 25, 2026 (announced via 6-K filed June 8, 2026). Fabry: Phase 3 (NCT05280548, n=104, evaluating left-ventricular-mass index) is active but not recruiting; estimated primary completion May 15, 2026 has passed with no results posted in local data; full completion Dec 6, 2027. GM2 gangliosidosis: Phase 3 (NCT04221451, n=75, Tay-Sachs/Sandhoff) is TERMINATED with results (completed Dec 26, 2024).
The Two-Sided Case
Upcoming Catalysts
- FDA PDUFA decision for Gaucher type 3 NDA — target action date November 25, 2026
- Potential topline disclosure from the Phase 3 Fabry trial (NCT05280548) — estimated primary completion May 15, 2026 passed; results not yet posted in local data
- Full Fabry trial completion estimated December 6, 2027
- Any regulatory filings outside the US (EU/Japan) for Gaucher type 3
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Sanofi 6-K SNY ·Originating report